The ANP32A Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted population derived from the A-549 human lung adenocarcinoma cell line. This polyclonal knockout product offers a heterogeneous pool of cells with targeted disruption of the ANP32A gene, providing a loss-of-function model for studying ANP32A-dependent processes. Unlike monoclonal cell lines, this polyclonal format retains population-level genetic diversity while abrogating ANP32A expression, making it suitable for bulk biochemical and functional analyses where clonal variation is not desired.
A-549 cells, originally isolated from a human lung adenocarcinoma, are widely used as a model of alveolar type II pulmonary epithelium. These adherent epithelial cells exhibit characteristics of lung adenocarcinoma and are a cornerstone in oncogenic research, particularly for investigating molecular mechanisms of lung cancer, drug responses, and signaling pathways. The A-549 line’s well-documented growth properties and susceptibility to genetic manipulation make it an ideal host for CRISPR-based gene editing.
ANP32A (acidic leucine-rich nuclear phosphoprotein 32 family member A) is a multifunctional protein that acts as a histone acetylation inhibitor through its role in the INHAT (inhibitor of acetyltransferases) complex, where it interacts with SET/TAF-I?? to mask histones from histone acetyltransferases such as p300 and CREBBP. ANP32A thereby represses transcription by preventing acetylation of histone H3 and histone H4. It is regulated by upstream oncogenic stimuli, including MYC signaling, and modulates downstream MYC target genes. Additionally, ANP32A participates in apoptosis regulation and PP2A inhibition, interacting with importin ?? for nuclear transport. Knockout of ANP32A is predicted to relieve transcriptional repression, leading to increased histone acetylation and derepression of genes involved in proliferation and survival.
In the A-549 lung adenocarcinoma background, disruption of ANP32A is expected to alter the epigenetic landscape, enhancing histone acetylation and reactivating gene expression programs that may influence tumor cell growth and apoptosis. Given ANP32A’s implication in multiple cancers including lung adenocarcinoma, prostate cancer, breast cancer, and neuroblastoma, this knockout model serves as a critical tool for dissecting the role of chromatin remodeling in oncogenesis. The polyclonal population allows for robust assessment of ANP32A’s contribution to A-549 cell behavior, particularly in pathways governed by MYC and histone acetyltransferases.
This product is well-suited for a range of applications including epigenetic regulation studies in lung cancer, proliferation and apoptosis assays, and drug sensitivity screening. Researchers can employ Western blotting to monitor changes in histone H3 and H4 acetylation marks, RT-qPCR to quantify expression of MYC target genes, and chromatin immunoprecipitation to map acetylated histones at genomic loci. Proliferation assays and apoptosis assays further enable functional characterization of the knockout phenotype. This polyclonal knockout model provides a versatile resource for investigating ANP32A-dependent mechanisms in cancer biology. For additional technical support or product inquiries, please contact Ascent Research.
